Pulmonary Cell News Volume 9.24 | Jun 24 2020

May 12, 2022

2020-06-25 | PULCN 9.24

Pulmonary Cell News by STEMCELL Technologies

Vol. 9.24 – 25 June, 2020

TOP STORY

Discovery of a Potent and Selective Covalent Inhibitor and Activity-Based Probe for the Deubiquitylating Enzyme UCHL1, with Anti-Fibrotic Activity

Investigators demonstrated that potent and selective ubiquitin carboxy-terminal hydrolase L1 (UCHL1) inhibitors blocked pro-fibrotic responses in a cellular model of idiopathic pulmonary fibrosis, supporting the potential of UCHL1 as a potential therapeutic target in fibrotic diseases.
[Journal of the American Chemical Society]

Abstract

PUBLICATIONSRanked by the impact factor of the journal

PEBP1 Acts as a Rheostat between Prosurvival Autophagy and Ferroptotic Death in Asthmatic Epithelial Cells

The concomitant activation of ferroptosis and autophagy by 15-lipoxygenase-1–PE-binding protein-1 complexes and their hydroperoxy-phospholipids revealed a pathobiologic pathway relevant to asthma and amenable to therapeutic targeting.
[Proceedings of the National Academy of Sciences of the United States of America]

Abstract

Copper-Dependent Biological Effects of Particulate Matter Produced by Brake Systems on Lung Alveolar Cells

Investigators studied the cell toxicity of particulate matter produced by different combinations of braking discs and pads containing different amounts of copper.
[Archives of Toxicology]

Abstract

LUNG CANCER

Multiple Low Dose Therapy as an Effective Strategy to Treat EGFR Inhibitor-Resistant NSCLC Tumors

Researchers showed that as little as 20% of the individual effective drug doses was sufficient to completely block MAPK signaling and proliferation when used in 3D or 4D inhibitor combinations.
[Nature Communications]

Full Article

Synergistic Effects of Bcl-2 Inhibitors with AZD9291 on Overcoming the Acquired Resistance of AZD9291 in H1975 Cells

Significant upregulation of Bcl-2 was found in AZD9291-resistant H1975 cells compared with H1975, which may constitute an important resistant mechanism of acquired resistance to AZD9291.
[Archives of Toxicology]

Abstract

YBX1 Mediates Autophagy by Targeting p110β and Decreasing the Sensitivity to Cisplatin in NSCLC

Scientists analyzed the expression and clinical significance of Y-box binding protein 1 (YBX1) and markers of autophagy in NSCLC and examined their roles in regulating sensitivity to cisplatin in non-small cell lung cancer (NSCLC).
[Cell Death & Disease]

Full Article

Vanadium(V/IV)–Transferrin Binding Disrupts the Transferrin Cycle and Reduces Vanadium Uptake and Antiproliferative Activity in Human Lung Cancer Cells

Binding of V(V) or V(IV) to transferrin in cell culture medium drastically reduced its cellular uptake and antiproliferative activity in the A549 cell line that expresses transferrin receptor 1.
[Inorganic Chemistry]

Abstract Graphical Abstract

miR-223 Regulates Autophagy Associated with Cisplatin Resistance by Targeting FBXW7 in Human Non-Small Cell Lung Cancer

Investigators found that the level of miR-223 was significantly positively correlated with cisplatin resistance. miR-223 overexpression made NSCLC cells resistant to cisplatin treatment.
[Cancer Cell International]

Full Article

A Synthetic Coumarin Derivative (4-Flourophenylacetamide-Acetyl Coumarin) Impedes Cell Cycle at G0/G1 Stage, Induces Apoptosis, and Inhibits Metastasis via ROS-Mediated p53 and AKT Signaling Pathways in A549 Cells

Scientists investigated the mechanism by which 4‐FPAC induced cytotoxicity and arrested the progression of cell cycle as well as metastasis in A549.
[Journal of Biochemical and Molecular Toxicology]

Abstract

Virtual Conference Exhibition: Pluripotent Stem Cells

REVIEWS

MicroRNA and ROS Crosstalk in Cardiac and Pulmonary Diseases

The authors focus on the complex crosstalk between miRNAs and ROS in diseases of the cardiac and pulmonary compartments.
[International Journal of Molecular Sciences]

Full Article

INDUSTRY AND POLICY NEWS

Achilles Therapeutics Doses First Patient in Phase I/II Study in Advanced Non-Small Cell Lung Cancer

Achilles Therapeutics announced that it has dosed the first patient in a Phase I/II CHIRON study of a clonal neoantigen T cell therapy in patients with advanced non-small cell lung cancer.
[Achilles Therapeutics (GlobeNewswire, Inc.)]

Press Release

aTyr Pharma Announces Dosing of First Patient in Phase II Trial of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications

The study is expected to enroll 30 patients at up to 10 centers in the US and the company expects to have the majority of centers enrolling within the coming weeks.
[aTyr Pharma.]

Press Release

CDC Broadens Guidance on Americans Facing Risk of Severe COVID-19

The Centers for Disease Control and Prevention on Thursday broadened its warning about who is at risk of developing severe disease from Covid-19 infection, suggesting even younger people who are obese or have other health conditions can become seriously ill if they contract the virus.
[STAT News]

Editorial

FEATURED EVENT

Discovery of a Potent and Selective Covalent Inhibitor and Activity-Based Probe for the Deubiquitylating Enzyme UCHL1, with Anti-Fibrotic Activity

PEBP1 Acts as a Rheostat between Prosurvival Autophagy and Ferroptotic Death in Asthmatic Epithelial Cells

Copper-Dependent Biological Effects of Particulate Matter Produced by Brake Systems on Lung Alveolar Cells

Multiple Low Dose Therapy as an Effective Strategy to Treat EGFR Inhibitor-Resistant NSCLC Tumors

Synergistic Effects of Bcl-2 Inhibitors with AZD9291 on Overcoming the Acquired Resistance of AZD9291 in H1975 Cells

YBX1 Mediates Autophagy by Targeting p110β and Decreasing the Sensitivity to Cisplatin in NSCLC

Vanadium(V/IV)–Transferrin Binding Disrupts the Transferrin Cycle and Reduces Vanadium Uptake and Antiproliferative Activity in Human Lung Cancer Cells

miR-223 Regulates Autophagy Associated with Cisplatin Resistance by Targeting FBXW7 in Human Non-Small Cell Lung Cancer

A Synthetic Coumarin Derivative (4-Flourophenylacetamide-Acetyl Coumarin) Impedes Cell Cycle at G0/G1 Stage, Induces Apoptosis, and Inhibits Metastasis via ROS-Mediated p53 and AKT Signaling Pathways in A549 Cells

MicroRNA and ROS Crosstalk in Cardiac and Pulmonary Diseases

Achilles Therapeutics Doses First Patient in Phase I/II Study in Advanced Non-Small Cell Lung Cancer

aTyr Pharma Announces Dosing of First Patient in Phase II Trial of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications

CDC Broadens Guidance on Americans Facing Risk of Severe COVID-19

Life Science Innovation Northwest Conference

> See All Events

Postdoctoral Researcher – Inhalation and Developmental Toxicology

Postdoctoral Research Fellow – Biology of Small Cell Lung Cancer

Postdoctoral Fellow – Lung Cancer Biology

Postdoctoral Positions – Single Molecule Biology

Postdoctoral Research Fellow – Viral and Bacterial Lung Infections

> See All Jobs